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Abstract
We briefly highlight the growing body of recent evidence linking unprotected oral sex with the development of
some types of head and neck cancer in younger patients. These tumours appear to be increasing in incidence
although the development of more sensitive methods of HPV detection may be a confounding factor.
Review
The incidence of head and neck squamous cell carcin-
oma (HNSCC) has been increasing over the last 30 years.
It is the 6th leading cause of cancer mortality in the
world. Usually these cancers present with advanced
metastatic disease causing high morbidity and mortality
[1,2]. The poor prognosis of these tumours has remained
at around 30–45% despite apparent advances in therapy
(i.e. radiotherapy and chemotherapeutic regimens) and
confounding by ‘lead time bias’. The most important risk
factors so far identified are tobacco and alcohol. These
appear to have a synergistic effect on the mucosal sur-
faces. Rodriguez et al., found a 20-fold increased risk of
oropharyngeal cancer below age 46 for heavy smokers,
and a 5-fold increase for heavy drinkers; if there was
both heavy drinking and smoking, this combination led
to an almost 50-fold increase in risk [3].
Interestingly however, in the US the percentage of
smokers reduced from 42.5% (1965) to 20.9% (2005) with
an associated fall in the traditional subset of HNSCC,
however the rates of oropharyngeal cancer especially of
the tongue and tonsil have increased again over the last
30 years and are also reflected in European studies [4–7].
This reduction in smoking exposure was also found in
RTOG 9003 and calls into question: how much of the
improvements in absolute survival observed in clinical
trials over time are due to changes in therapy over time
rather than being driven by social factors? [8]. A recent
study by Jerjes et al. came to the conclusion that tobacco
and alcohol reduction/cessation at time of diagnosis
tends to reduce mortality in oral cancer patients [9].
Viral genes interfere with cell replication control
mechanism. Many other viruses are known to predispose
to tumours (Table 1). Viruses associated with tumors can
be classified into two types depending on the nucleic
acid in the viral genome and the nature of strategy to in-
duce malignant transformation. The RNA tumor viruses
(retroviruses), when they infect cells, the viral RNA is
copied into DNA by reverse transcription and the DNA
is introduced into the host genome, where it persists and
can be inherited by subsequent generation of cells.
Transformation of the infected cells can be traced to
oncogenes that are carried by the viruses. The viral
oncogenes are closely similar to cellular genes, the
proto-oncogenes, which code for components of the cel-
lular machinery that regulates cell proliferation, differen-
tiation, and death. While, DNA viruses replicate lytically
and kill the infected cells. Transformation happens in
non-permissive cells where the infection cannot advance
to viral replication. The transforming capability of DNA
tumor viruses has been traced to numerous viral pro-
teins that work together to stimulate cell proliferation,
overriding some of the normal growth regulator mechan-
isms in the infected cell and its progeny. Different from
retroviral oncogenes, DNA virus oncogenes are indis-
pensable components of the viral genome and have no
counterpart in the normal host cells. Some of these viral
proteins bind to the protein yields of two key tumor sup-
pressor genes of the host cells, the retinoblastoma gene
and the p53 gene, deactivating them and thereby permit-
ting the cell to replicate its DNA and divide [1–9].
Recent data have now attributed a human papilloma-
virus (HPV) aetiology to a subset of head and neck
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Table 1 Viruses are known to predispose to tumours
(some examples are included in the table)
Hepatitis B virus and liver adenocarcinoma
EBV, Burkett’s lymphoma and nasopharyngeal carcinoma
HIV and Non-Hodgkin’s lymphoma, Kaposi sarcoma. . .etc.
HPV and cervical cancer
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atine tonsils (oral cavity) [8,10]. HPV has also been
implicated in nearly 100% of cervical cancers, 66% of
anal cancers, 43% of vaginal/vulval cancers, 44% of
penile cancers and almost 15% of oropharyngeal tumours
[11] and are implicated in up to 60% of head & neck
cancers in the US [8].
The HPV family of DNA-viruses preferentially infects
squamous epithelial cells with over a 100 separate geno-
types and more than 40 of which cause genital infections.
They represent the most common sexually transmitted
disease worldwide with nearly 80% of infection rates in
sexually active adults in the US of at least one HPV type
by the age of 50 years. The peak prevalence occurs dur-
ing early sexual activity (adolescence and young adult-
hood) which declines with age with HPV 16 being the
most common [12]. Most people who get the infection
do not develop sequalae; but a minority develops cancer
as a consequence of the infection. HPV can induce a
spectrum of epithelial disease ranging from asymptom-
atic infection, simple papilloma through to frank squa-
mous cell carcinoma (SCC). The virus tends to manifest
at epithelial junctional areas (i.e. where the epithelium
changes from stratified squamous to simple cuboidal,
collumnar or contains lymphoid tissue). This may also
coincide with areas of differing embryological origins.
Common areas affected are the oropharynyx, including
the tonsils and tongue base. These areas are notorious as
residences for ‘occult’ primaries, usually presenting at a
more advanced stage in younger patients.Table 2 HPV infection is likely to be sexually acquired: vagina
Sexual behavior Control patients Patients with
Oropharyngeal Cancer








Modified from D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. C
Med. 2007 May 10;356(19):1944–56.Human papillomavirus (HPV) as a risk factor was first
suggested in 1983 by Syrjänen et al., who noted that 40%
of the studied cancers contained histological and mor-
phological similarities with HPV-associated lesions [13].
Subsequently, there is growing evidence strongly support
a role for HPV in a subset of HNSCC. These head and
neck cancers tends to occur in younger people, origi-
nates from the oropharynx (particularly the tonsils), and
are poorly differentiated, and are related to sexual
practices.
Work by D’Souza and colleagues recently showed HPV
infection is likely to be sexually acquired [14] with
increased risk of oropharyngeal cancer with either many
(more than 26) lifetime vaginal-sex partners or six or
more lifetime oral-sex partners. Obviously the issue is
confounded by the use of and availability of mucosal
protection for genital rather than oral intercourse
(Tables 2 and 3).
Establishing the evidence for a causal role for HPV in
a subset of HNSCC has been compounded by the het-
erogeneity of the tumours and multiple primary anatom-
ical sites. These studies employed different detection
techniques; different sampling methods and different
storage procedures. The non-standardization of these
multiple variables has confused the issue [1].
Serological and molecular markers of HPV infection
are also associated with increased risks of HNSCC.
Hansson et al. found a strong association between the
detection of high-risk HPV DNA in the oral cavity and
oropharyngeal carcinoma (OR 230; CI 45–1200) after
adjusting for alcohol and tobacco usage [15].
The most common types of infection associated with
cancer are HPV-16 [16] and to a lesser extent 18
(Table 4) but other high risk mucosal types exist. Mork
et al. demonstrated an increased risk of greater than 2-
fold for subsequently developing oral cancer if there was
HPV-16 seropositivity. The rates of HPV-16 infection
have increased from 23% (1970s) to 68% (2000’s),l-sex and oral sex partners
Adjusted Odds
ratio (95% CI) HPV 16+ Patients
Adjusted Odds
ratio (95% CI) All patients
1.0 1.0
2.7 (1.4–5.5) 2.2 (1.2–4.0)
4.2 (1.8–9.4) 3.1 (1.5–6.5)
1.0 1.0
3.8 (1.0–14.0) 1.9 (0.8–4.5)
8.6 (2.2–34.0) 3.4 (1.3–8.8)
ase-control study of human papillomavirus and oropharyngeal cancer. N Engl J
Table 3 Most common types of infection associated with cancer are HPV-16 and to a lesser extent 18
Measures of HPV Prevalence (%) Odds SimplePara> HPV 16+ Patients
Control Oropharyngeal cancer Adjusted compared to control (1.0)
HPV-16 serology 7 57 32.2 (14.6–71.3)
Oral HPV-16 infection 4 32 14.6 (6.3–36.6)
All Oral HPV infection 6 37 12.3 (5.4–26.4)
HPV-16 E6 or E7 serology 4 64 58.4 (24.2–138.3)
Modified from D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J
Med. 2007 May 10;356(19):1944–56.
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methodologies [17]. It is estimated that individuals with
an oral HPV 16 infection have between a 15- and 200-
fold increase in risk of developing oropharynx cancer [8].
Oral sex with multiple partners is one of the significant
risk factors for oral cancer and oropharyngeal cancer.
Young people, who increasingly practice oral sex espe-
cially with many partners, may be driving the increase in
these cancers.
The pathogenesis of viral induced oncogenesis is pre-
sumably similar to cervical cancer development but het-
erogeneity and the existence of multiple pathways to
carcinogenesis is highly likely. This is also likely to reflect
a difference in life cycles of the different HPV subtypes
in different mucosal locations, with an associated differ-
ence in mucosal immune responses [1]. It must be
remembered that the oral cavity is a battlefield of healing
mucosal micro abrasions which could in the right cir-
cumstances of altered local host defenses allow viral in-
culcation, infection and entrenchment leading to somatic
genetic change. Changes in immuno-tolerance [16] at
these ‘special’ immuno-modulating sites (the oropharyn-
geal parts of Waldeyers ring of lymphoid/squamous tis-
sue) combined with further environmental triggers then
lead to cancerous changes. Basically, viral “genes load
the gun and environment pulls the trigger”.
The high risk human papilloma viruses (types 16 and
18) contain the transforming genes E6 and E7. Although
these gene products have a multitude of effects, in es-
sence E6 binds to and inactivates the p53 suppressor
gene resulting in tolerance of DNA errors and tumour
entrenchment. Whilst E7 binds the RB suppressor gene,








HPV prevalence (%) 35.6 23.5 24
HPV 16 prevalence (%) 86.7 68.2 69.2
HPV 18 prevalence (%) 1 8 3.9
Modified from Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human
papillomavirus types in head and neck squamous cell carcinomas worldwide: a
systematic review. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467–75.continuous proliferation. This interaction between viral
derived products and intrinsic cellular proteins inhibits
apoptosis in infected cells, enabling them to both survive
and undergo continuous growth which inhibits differen-
tiation. This has been found quite readily in oral kerati-
nocytes and epithelial cells [18,19].Clinical implications of HPV+ in head and neck
cancers
Accumulating evidence suggests that HPV+ status is an
important prognostic factor associated with a favourable
outcome after treatment in head and neck cancers [19–
23]. Prospective multi-centre clinical study (as opposed
to the retrospective studies previously discussed), Gilli-
son et al. demonstrated that patients with HPV+
tumours had better response rates after induction
chemotherapy (82% vs. 55%), and after chemoradiation
treatment (84% vs. 57%) compared to patients with
HPV- tumours. Patients with HPV+ tumours had an
improved overall survival of 33%, and after adjustment
for age, tumour stage and ECOG status, a lower risk of
progression and death from any cause, compared to
those with HPV- tumours [24]. About 85% of patients
with HPV+ tumors are still alive within 5 years of their
cancer diagnosis, compared with about 45% of those
with non-HPV tumors [8]. These studies provided strong
evidence that HPV+ tumour status was both associated
with a better response to current treatment regimes, but
also with a much improved survival rate, and risk of pro-
gression, compared to HPV- tumour status. It maybe
that the HPV+ tumours are different in both their aeti-
ology and biology from the purely smoking and alcohol
associated HPV- tumours, hence their differing response
to treatment [8,25]. The better prognosis and treatment
responses to chemotherapy and radiotherapy by HPV+
tumours may mean that HPV status detection is
required to better plan and individualise patient treat-
ment regimes. It is now common practice to send initial
tumour biopsy material for HPV sub-typing and fast
track these patients through chemoradiation schedules
with anti-angiogenic antibody.
Finally, it may be that the subgroup of head & neck
tumours often in younger patients are induced by
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to oral-sex practitioners and promote the use of barrier
methods (condoms, oral dams). We would also advocate
the early specialist referral of any patient presenting with
i.e. persistent unilateral oropharyngeal symptoms or
signs (>3weeks) even in the absence of the ‘traditional
predisposing factors’ (smoking, alcohol, age) to head &
neck squamous cell carcinoma. One would welcome vac-
cination schedules which include the HPV subtypes asso-
ciated with head and neck cancer. Unfortunately not all
the commercially available vaccines include the subtypes
in question although there is some evidence of limited
cross-over protection.
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